TABLE 2.
Adverse events at least possibly related to the treatment administration and occurring in >10% of patients in case of grade 1/2 events and all events in case of grade 3/4 events. All events were graded according to the Common Terminology for Adverse Events version 4.03
| Grade 1/2 | Grade 3/4 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose‐level | −1 | 1 | 2 | 3 | 4 | All (%) | −1 | 1 | 2 | 3 | 4 | All (%) |
| Adverse event | ||||||||||||
| Alanine aminotransferase increased | 1 | 1 | 1 | 3 (13) | 1 | 1 (4) | ||||||
| Anemia | 1 | 1 (4) | 1 | 2 | 1 | 4 (17) | ||||||
| Anorexia | 1 | 2 | 1 | 4 (17) | ||||||||
| Aspartate aminotransferase increased | 1 | 1 | 2 (8) | 1 | 1 (4) | |||||||
| Dysgeusia | 2 | 1 | 3 (13) | |||||||||
| Fatigue | 2 | 2 | 1 | 3 | 8 (33) | |||||||
| Nausea | 6 | 3 | 2 | 11 (46) | ||||||||
| Neutrophil count decreased | 1 | 1 | 2 | 1 | 4 (17) | 2 | 2 (8) | |||||
| Platelet count decreased | 4 | 2 | 2 | 8 (33) | 1 | 1 | 2 (8) | |||||
| Vomiting | 1 | 1 | 2 | 4 (17) | ||||||||